Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MCS110 |
Synonyms | |
Therapy Description |
Lacnotuzumab (MCS110) is a monoclonal antibody that binds CSF1 and prevents receptor binding and subsequent receptor activation, and leads to reduction of tumor-related bone destruction (Cancer Res; 2009 Apr 18-22; Abstract nr DDT02-2). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MCS110 | Lacnotuzumab | CSF1 Antibody 2 | Lacnotuzumab (MCS110) is a monoclonal antibody that binds CSF1 and prevents receptor binding and subsequent receptor activation, and leads to reduction of tumor-related bone destruction (Cancer Res; 2009 Apr 18-22; Abstract nr DDT02-2). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01643850 | Phase II | MCS110 | MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCTTS) | Completed | USA | CHE | 0 |
NCT02435680 | Phase II | MCS110 Carboplatin + Gemcitabine | Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) | Completed | USA | TUR | ITA | FRA | ESP | DEU | BEL | AUT | AUS | 3 |